Bridgeway Capital Management’s Argos Therapeutics, Inc. ARGS Stock Holding History

Bridgeway Capital Management’s Portfolio ARGS Stock Details ARGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-6,076	Closed	-$595K	–	1543
2016 Q4	$595K	Hold	6,076	–	–	0.01%	1017
2016 Q3	$604K	Sell	6,076 -720	-11%	-$75.2K	0.01%	1006
2016 Q2	$833K	Buy	6,796 +2,725	+67%	+$364K	0.01%	850
2016 Q1	$521K	Buy	4,071 +2,071	+104%	+$167K	0.01%	1030
2015 Q4	$92K	Hold	2,000	–	–	﹤0.01%	1380
2015 Q3	$194K	Hold	2,000	–	–	﹤0.01%	1318
2015 Q2	$274K	Hold	2,000	–	–	0.01%	1276
2015 Q1	$356K	Hold	2,000	–	–	0.01%	1208
2014 Q4	$400K	Buy	+2,000	New	+$360K	0.01%	1144

Other funds holding ARGS

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Bridgeway Capital Management's ARGS Position: Q1 2017 in Review

Bridgeway Capital Management sold out of Argos Therapeutics, Inc. (ARGS) in Q1 2017, closing a stake of 6,076 shares — an estimated $595K sold.

Bridgeway Capital Management first reported a position in ARGS in Q4 2014 and held it in 9 quarters. The position peaked at $833K in Q2 2016. 43 funds tracked by Wall St. Rank hold ARGS as of Q1 2017.

Bridgeway Capital Management reported no remaining Argos Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
Bridgeway Capital Management sold 6,076 Argos Therapeutics, Inc. shares in Q1 2017, an estimated $595K.
Bridgeway Capital Management first reported a position in Argos Therapeutics, Inc. in Q4 2014 and held it in 9 quarters.
Bridgeway Capital Management's Argos Therapeutics, Inc. position peaked at $833K in Q2 2016.
43 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q1 2017.

Based on Bridgeway Capital Management's 13F filing for Q1 2017, filed 15 May 2017.